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Background. The use of a ﬁxed-combination antibiotic corticosteroid for infection prophylaxis in Asian patients undergoing
phacoemulsiﬁcationhas not been reported. Methods. A 15-day, open-label, single-arm trial of 64 patients for phacoemulsiﬁcation
with intraocular lens (IOL) implantation is described. Patients applied moxiﬂoxacin 0.5%/dexamethasone 0.1% (Vigadexa) eye
drops four times daily before and until 15 days after surgery. Anterior chamber (AC) reaction, visual acuity, ocular pain and signs,
and intraocular pressure (IOP) were assessed at baseline and on postoperative days 1, 3, 8, and 15. Results. At day 15, 55 (91.7%)
patients scored 0 (<5 cells) in AC reaction. No surgery-related infection occurred. Mean best-corrected visual acuity improved
0.5 logMAR from baseline to 0.0 logMAR (P<. 0001). Mean IOP remained at 12-13 mm Hg over the 15-day treatment. Only 2
patients(3.1%)reported minimumocularpain.Two (3.1%)patients were shifted to prednisoloneacetate forsevereinﬂammation.
At the end of the study period, 8.3% were given ﬂuorometholone for 1 week for AC reaction grade >0. No drug-related adverse
event was reported. Conclusion. Following phacoemulsiﬁcation and IOL implantation, the topical combination moxiﬂoxacin
0.5%/dexamethasone 0.1% was eﬀective in preventing infection and controlling inﬂammationand was well tolerated.
1.Introduction
Cataract surgery with intraocular lens (IOL) implantation is
the most common ophthalmic surgical operation. The mean
annual incidence of postoperative endophthalmitis (POE)
among cataract patients ranges from 0.05 to 0.14% [1–5].
In practice, ophthalmologists apply topical antibiotic drops
to prevent this rare but potentially devastating complication.
[3, 6–8]. An American Society of Cataract and Refractive
Surgery (ASCRS) survey (N = 1312) showed that fourth-
generation ﬂuoroquinolones were preferred by most sur-
geons (81%) for infection prophylaxis after surgery [9]. The
topical fourth-generation ﬂuoroquinolone moxiﬂoxacin has
proven advantageous over older ﬂuoroquinolones as well
as other topically available antimicrobials. It has a broader
spectrum of action and excellent penetration into eye tissues
and is able to deliver a concentration thousands of times the
minimum inhibitory concentration [10–13].
Topical corticosteroids such as dexamethasone are
applied with infection prophylaxis to minimize, if not
eliminate, the inﬂammatory reaction expected after surgery.
It has been reported that treatment with combined steroid-
antibiotic eye drops was eﬀective in preventing infection and
controlling inﬂammation after phacoemulsiﬁcation and IOL
implantation [14–16].
In our setting, as well as in other developing nations,
ﬁnancial capabilities of patients and expenditure restrictions
from health care organizations demand cost eﬀectiveness.
A ﬁxed-combination eye preparation not only helps in
cutting costs but also improves patient compliance due to
convenience in dosing and application. The combination
formulation of moxiﬂoxacin 0.5%/dexamethasone 0.1%2 Journal of Ophthalmology
(Vigadexa, Alcon Laboratories, Inc., Fort Worth, Tex, USA)
is available in the market. Its eﬃcacy and tolerability in
ophthalmic surgery has been evaluated [15, 17]. However,
its clinical use in Asian patients with cataract has not been
reported. The purpose of the present study was to evaluate
the eﬃcacy and tolerability of the combination formulation
in the prevention of postoperative inﬂammation and infec-
tion following phacoemulsiﬁcation in predominantly Asian
patients.
2.Materialsand Methods
2.1. Patients. This 15-day, open-label, and single-arm clin-
ical trial was conducted at the American Eye Center,
Philippines. Thecenter’sinstitutionalreviewboard approved
the study protocol, which followed the principles set forth in
the Declaration of Helsinki. Informed consent was obtained
from each patient prior to their participation in the study.
Adult patients (≥18 years) with a diagnosis of cataract
underwent clear cornea incision phacoemulsiﬁcation with
IOL implantation. Surgery was performed in only one
eye in each patient. Patients who presented with the fol-
lowing conditions were excluded: uncontrolled glaucoma,
intraocular hypertension, diabetes mellitus, iris atrophy,
chronic or recurrent ocular inﬂammatory disease (i.e., iritis,
scleritis,uveitis,iridocyclitis,andrubeosisiridis),intraocular
inﬂammation, or ocular pain in the study eye prior to the
surgery. The use of any ocular antimicrobial drug within
30 days prior to enrollment in the study, nonsteroidal anti-
i n ﬂ a m m a t o r yd r u g so rs y s t e m i co rt o p i c a ls t e r o i d sw i t h i n1 4
dayspriorto enrollment, or a topicalprostaglandin analogue
four days prior to the surgery until the completion of the
study also excluded patients from the study.
2.2. Treatment. Patients were instructed to instill one drop
from a labeled bottle of moxiﬂoxacin 0.5%/dexamethasone
0.1% (Vigadexa) 4 times a day in the conjunctival sac of the
eye to be operated on beginning from day −1( 1d a yb e f o r e
the surgery) until day 15 (15 days after the surgery). On day
0 (surgery day), the patient was dosed by the study nurse.
A drop was applied prior to and upon completion of the
surgery.
The patients underwent phacoemulsiﬁcation (2.2mm
clearcornea incision) using the Inﬁniti Vision System(Alcon
Laboratories, Inc., Fort Worth, Tex, USA) followed by
implantation of a single-piece aspheric hydrophobic acrylic
IOL (Acrysof IQ, Alcon Laboratories, Inc., Fort Worth,
Tex, USA) in the capsular bag. Viscoelastics used were
sodium chondroitin sulfate-sodium hyaluronate (Viscoat,
AlconLaboratories)and sodiumhyaluronate (Provisc, Alcon
Laboratories) and were removed using coaxial irrigation
and aspiration with a vacuum level of 600mmHg. All
cases were done using the same surgical technique. Pre-
operative and intraoperative medications included tropi-
camide/phenylephrine, povidone-iodine local antiseptic and
topical proparacaine HCl, and intracameral lidocaine anes-
thesia.
2.3. Patient Evaluation. During the screening visit (within
14 days prior to surgery), baseline values of both eyes were
recordedforbest-correctedvisualacuity(BCVA)inlogMAR,
and intraocular pressure (IOP) was measured by Goldman
applanation tonometry. Patients were examined for the
presence of anterior chamber (AC) cells and ﬂare and any
pathology of the eyelids, conjunctiva, and cornea through
slit-lamp biomicroscopy. A dilated fundus examination was
performed to examine the retina, macula, choroid, vitreous,
and optic nerve.
Patients were seen postoperatively on days 1, 3, 8,
and 15. At each visit, patients were examined for signs
of infection, inﬂammation, and ocular pain. The BCVA
and IOP measurements were taken. AC inﬂammation, a
major criterion of eﬀectiveness, was evaluated based on the
number of cells per high-power ﬁeld measured using the
narrowest slit beam of the lamp (0.5 at a height of 8mm)
and was recorded on a 0–4 point scale, where 0 indicates
less than 5 cells, 1 = 5–10 cells (mild), 2 = 11–20 cells
(moderate), 3 = 21–50 cells (marked), and 4 indicates more
than 50 cells (hypopyon, severe). Ocular pain was scored by
patients subjectively (0 = none, 1 = minimum, 2 = mild,
3 = moderate, 4 = moderately severe, and 5 = severe).
Additionally, structural changes and signs of inﬂammation
in the eyelids/conjunctiva and cornea were evaluated by slit
lamp (0 = absence of active inﬂammation and 1 = presence
of active inﬂammation). A dilated fundus examination was
p e r f o r m e da te x i tf r o mt h es t u d y .
2.4. Statistical Analysis. All patients receiving the drug (N =
64) were evaluated for safety. Those with at least one follow-
up visit after the surgery were included in the per-protocol
(PP) analysis (n = 60). A Fisher’s exact test of independence
was employed to evaluate the diﬀerences in the percentage of
patients with a score of zero for AC cells at each visit before
and after treatment. The ocular signs score was analyzed
using the Cochran-Mantel-Haenszel (CMH) test with rank
score. A Fischer’s exact test was applied to evaluate ocular
pain.At-testwasusedtocompareIOPchangefrombaseline.
Only data from the operatedeye were analyzed and reported.




Sixty-four patients (27 male and 37 female) were enrolled in
the study. All were Asians except for two Caucasians. The
mean age was 68 years ± 11.4 years (SD) (range from 34
to 86 years). Four patients did not complete the study. Two
were lost to followup, and two were shifted to moxiﬂoxacin
(Vigamox) and prednisolone acetate (Pred Forte) on day 1
due to severe ocular inﬂammation.
An increased inﬂammatory response was observed for
the ﬁrst few days after surgery which gradually declined
until day 15 (Table 1). On day 1, 85% of patients had
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Figure1:Changeinthebest-corrected visualacuityoftheoperative
e y eb e f o r ea n da f t e rt r e a t m e n t .
of patients with grade 3 AC cells decreased to 1.7% on
day 3. On day 15, 91.7% had grade zero AC cells and
only 1 patient had moderate inﬂammation. At the end of
the study, 96.9% did not experience eye pain, while 3.1%
rated their eye pain as minimum. Signs of active inﬂam-
mation in the eyelid/conjunctiva and cornea signiﬁcantly
decreased from day 1 postoperatively to day 15. At day 1,
inﬂammation was documented in 9.4% (n = 6) of eyes in
the eyelid/conjunctiva, while the same was observed in the
cornea in 23.4% (n = 15) of eyes (Table 2). At the end of
the study, signs of inﬂammation in the eyelid/conjunctiva
and in the cornea were seen in only 1 eye and in 2 eyes,
respectively.
The BCVA improved from a mean of 0.5logMAR preop-
erativelyto 0.0logMARonday 15 (P<. 0001)(Figure 1). On
the day of surgery, the mean IOP was recorded at 17mmHg.
The mean IOP was maintained postoperatively in the range
of 12-13mmHg over the course of the 15-day treatment
(Figure 2). No abnormality was found in the fundus of the
study eyes at exit from the study. No drug-related adverse
event was reported.
4.Discussion
Our study assessed the eﬃcacy of a ﬁxed-combination moxi-
ﬂoxacin 0.5%/dexamethasone 0.1% formulation (Vigadexa)
in the prevention of postoperative inﬂammation and infec-
tion following phacoemulsiﬁcation in mostly Asian patients.
At the completion of the study, a score of 0 for AC cells
less than 5 was found in 91.7% (55/60) of eyes. This is
comparable to the ﬁgure reported in a previous study which
was97%[15].PatientswithanACreactionhigherthangrade
0 did not complain of any ocular discomfort or blurring of
vision. They were, however, given topical ﬂuorometholone
four times daily dosing for one week after discontinuing
Vigadexa with resulting resolution of the inﬂammation.
On the 1st postoperative day, more than half (55%)
had moderate to marked AC cell grading, which decreased
to 21.7% by day 3 and to 3.3% by day 8 (Table 1). This
is consistent with the postoperative AC reaction pattern
the investigators observed in cases where separate antibiotic
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Figure 2: Change in the IOP of the operative eye before and after
treatment.
and corticosteroid eye drops were given after cataract
surgery. The postoperative inﬂammatory pattern in the eye-
lid/conjunctiva and cornea was judged by the investigators
as consistent with previous observations. All these were
reﬂective of the mild ocular changes expected to occur as a
result of surgery.
In this small population of 60 eyes, no surgery-related
infection occurred. However, the rarity of the event and
the size of the study population did not allow us to make
statistically signiﬁcant conclusions about the eﬀectiveness of
the medication in preventing POE. Prior to our single-arm
trial, the eﬃcacy of the ﬁxed combination had already been
established in a study by Freitas et al. in a Brazilian popu-
lation [15]. In this randomized, parallel-group trial (N =
139), the combination moxiﬂoxacin 0.5%/dexamethasone
1% was as eﬀective in preventing infection and controlling
inﬂammation postoperatively compared to when its individ-
ual components were administered concurrently.
The current study also evaluated the safety and patient
acceptance of the ﬁxed-combination preparation of moxi-
ﬂoxacin 0.5% and dexamethasone 0.1%. The formulation
was well tolerated by patients; patients did not report
any discomfort during or immediately after its application.
No corneal or other ocular surface signs attributable to
medication toxicity as well as drug-related adverse events
were observed during the entire duration of the study. This
safety proﬁle mirrors that observed in the study by Freitas
et al. [15]. Good patient compliance was determined from
patient accountsduring follow-up consultations. This can be
attributed to the tolerability proﬁle of the drug and ease of
administration. Patients will comply with instilling an eye
drop that does not sting, burn, cause redness, or blur vision.
Furthermore, applying less number of drops makes it easier
for patients to remember and adhere to the dosing regimen.
With a combination preparation, patients no longer have to
wait a minimum of ﬁve minutes to instill a drop from a
separate medicationto preventa wash-out eﬀect[16, 18, 19].
Various ﬁxed-combination preparations have also shown
eﬃcacy and safety following cataract surgery. The formu-
lations of netilmicin-dexamethasone, tobramycin-dexam-
ethasone, and neomycin-polymyxin-dexamethasone eﬀec-
tively controlled postoperative inﬂammation and were well4 Journal of Ophthalmology
Table 1: Anterior chamber cells of operative eye, n (%).
Anterior chamber cells Baseline Day 1 Day 3 Day 8 Day 15
N 60 60 60 60 60
0 = Less than 5 cells 60 (100.0%) 2 (3.3%) 26 (43.3%) 49 (81.7%) 55 (91.7%)
1 = Mild: 5–10 cells 0 (0.0%) 25 (41.7%) 21 (35.0%) 9 (15.0%) 4 (6.7%)
2 = Moderate:11–20 cells 0 (0.0%) 24 (40.0%) 1 (20.0%) 2 (3.3%) 1 (1.7%)
3 = Marked: 21–50 cells 0 (0.0%) 9 (15.0%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
4 = Severe: Greater than 50 cells/hypopyon 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Table 2: Ocular signs of inﬂammationobserved in eyes, n (%).
Baseline Day 1 Day 3 Day 8 Day 15
Eyelid and conjunctiva
0 64 (100.0%) 58 (90.6%) 61 (95.3%) 63 (98.4%) 63 (98.4%)
1 0 (0.0%) 6 (9.4%) 3 (4.7%) 1 (1.6%) 1 (1.6%)
Cornea
0 64 (100.0%) 49 (76.6%) 57 (89.1%) 62 (96.9%) 62 (96.9%)
1 0 (0.0%) 15 (23.4%) 7 (10.9%) 2 (3.1%) 2 (3.1%)
0 = No evidence of active inﬂammatory signs or signiﬁcant structural changes or discharge.
1 = Presence of active inﬂammation signs or signiﬁcant structural change or discharge.
tolerated, as described in comparative trials with Caucasian
patients [16, 18, 20].
5.Conclusion
The ﬁxed-combination moxiﬂoxacin 0.5%/dexamethasone
0.1%formulationwasfoundtobewelltoleratedandeﬀective
in minimizing inﬂammation following cataract surgery in
Asians. Because Vigadexa is a relatively new medication,
f u r t h e rc l i n i c a lt r i a l sw i t hl a r g e rn u m b e ro fp a t i e n t sa r e
warranted to further demonstrate and conﬁrm its long-term
safety and eﬃcacy proﬁle, particularly in the prevention of
endophthalmitis.
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